CiteReady is an online personal knowledge management tool. Click to find out more!
 
Updated in 8/12/2020 12:04:37 PM      Viewed: 262 times      (Journal Article)
Current oncology reports 7 (5): 377-82 (2005)

Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.

Nicole Kounalakis , James S Goydos
ABSTRACT
The search is on for biomarkers for use in the diagnosis, staging, prognosis, and management of patients with melanoma. As with many types of cancer, the hematogenous spread of melanoma is a bad prognostic sign, and many groups have attempted to detect circulating melanoma cells in patients with different stages of melanoma. Some studies have used direct extraction of intact tumor cells from the peripheral blood and others the detection of surrogate markers of circulating melanoma cells, such as tyrosinase or MART-1. However, a correlation between the detection of intact melanoma cells in the circulation and prognosis is controversial. Many other biomarkers have also been studied, including lactate dehydrogenase, S100, TA90, and C-reactive protein. Much progress has been made, and preliminary studies have shown promise with many of these markers. Finally, the detection of tumor-specific circulating DNA has shown promise as a prognostic and diagnostic marker of disease in melanoma as well. In this review we examine the most promising biomarkers for use in patients with cutaneous melanoma.
DOI: 10.1007/s11912-005-0065-2      ISSN: 1523-3790